A Dual-RNA Guided CasZ Gene Editing Technology

Tech ID: 28913 / UC Case 2018-045-0

Patent Status

Country Type Number Dated Case
United Kingdom Issued Patent 2582482 05/17/2023 2018-045
United States Of America Issued Patent 11,453,866 09/27/2022 2018-045
United States Of America Issued Patent 11,441,137 09/13/2022 2018-045
United States Of America Issued Patent 11,371,031 06/28/2022 2018-045
United States Of America Issued Patent 11,180,743 11/23/2021 2018-045
China Published Application CN117487776A 02/02/2024 2018-045
United States Of America Published Application 20230323319 10/12/2023 2018-045
Hong Kong Published Application 40036150 05/21/2021 2018-045
Japan Published Application 2021-503278 02/12/2021 2018-045
Mexico Published Application MX/A/2020/00457 12/30/2020 2018-045
China Published Application CN111886336A 11/03/2020 2018-045
European Patent Office Published Application 3704239 A0 09/09/2020 2018-045
India Published Application 32/2020 08/07/2020 2018-045
Rep Of Korea Published Application 10-2020-0091858 07/31/2020 2018-045
Australia Published Application WO 2019/089820 05/09/2019 2018-045
Canada Published Application 3080493 05/09/2019 2018-045
Japan Published Application WO 2019/089820 05/09/2019 2018-045
New Zealand Published Application WO 2019/089820 05/09/2019 2018-045
New Zealand Published Application WO/2019/089820 05/09/2019 2018-045
Singapore Published Application WO 2019/089820 05/09/2019 2018-045

Additional Patents Pending

Brief Description

The CRISPR-Cas system is now understood to confer bacteria and archaea with acquired immunity against phage and viruses. CRISPR-Cas systems consist of Cas proteins, which are involved in acquisition, targeting and cleavage of foreign DNA or RNA, and a CRISPR array, which includes direct repeats flanking short spacer sequences that guide Cas proteins to their targets.  Class 2 CRISPR-Cas systems are streamlined versions in which a single Cas protein bound to RNA is responsible for binding to and cleavage of a targeted sequence. The programmable nature of these minimal systems has facilitated their use as a versatile technology that is revolutionizing the field of genome manipulation, so there is a need in the art for additional Class 2 CRISPR/Cas systems (e.g., Cas protein plus guide RNA combinations).


UC Berkeley researchers discovered a new type of Cas protein, CasZ.  (CasZ) is short compared to previously identified CRISPR-Cas endonucleases, and thus use of this protein as an alternative provides the advantage that the nucleotide sequence encoding the protein is relatively short.  The researchers have shown that the CRISPR CasZ protein and its variants can be used in a complex for specific binding and cleavage of DNA. The CRISPR CasZ complex utilizes a novel RNA and a guide RNA to perform double stranded cleavage of DNA and the complex is expected to have a wide variety of applications in genome editing and nucleic acid manipulation. 

Suggested uses

  • Genome editing
  • Genetic engineering
  • Gene therapy
  • Research tools (e.g., high-throughput screening of gene functions in cell lines and in vivo)
  • Creation of transgenic animal models



  • Adds additional versatility because of small size
  • Variant PAM


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Doudna, Jennifer A.

Other Information


CRISPR, gene editing, gene therapy, therapeutics,

Categorized As

Additional Technologies by these Inventors